Coronary artery disease is still a leading cause of morbidity and mortality and its prevalence is increasing. 1 However, in the last three decades, the mortality rate due to ischemic heart disease has decreased significantly, although with wide differences between countries. This reduction is due to the decline in the incidence of ST-segment elevation myocardial infarction (STEMI) in association with a fall in acute and long-term mortality following STEMI thanks to the implementation of timely reperfusion, antithrombotic therapy, and secondary prevention. 2 After the occlusion of an epicardial coronary artery, the myocardial area subtended by the occluded coronary artery is in jeopardy. This hypoperfused myocardium during the evolving myocardial infarction is defined as the area at risk (AAR). If ischemia persists with complete absence of blood flow, either antegrade or collateral, myocardial injury is meant to be irreversible leading to necrosis demarcation, with a wavefront progression from the subendocardium to the subepicardium. A timely reperfusion therapy may change the pathological features of myocardial infarction: coronary artery recanalization can avoid the transmural progression of myocardial necrosis and, most importantly, may stall necrosis evolution of AAR turning it in the salvaged myocardium. 3 Quantifying how much myocardium is salvaged by measuring the final infarct size in relation to the initial AAR is mandatory to evaluate the efficacy of reperfusion therapy. Although a number of non-invasive imaging methods have been settled to evaluate myocardial salvage, namely ECG-based scoring systems, angiographic scores, cardiac magnetic resonance imaging (CMR), and more recently functional computed tomography, for a long time the most-used technique to quantify myocardial rescue has been single-photon emission-computed tomography (SPECT). Assessment of AAR by SPECT is done by injecting 99m-Technetium (Tc)-labelled perfusion tracers just before revascularization and then acquiring images up to 8 hours after the procedure. Therefore, this method requires tracer availability in the catheterization laboratory on a 24 hours basis and it can be logistically demanding. Evaluation of final infarct size requires repeated SPECT perfusion imaging in a stable state, at least 120 hours after infarction, and preferably weeksmonths following revascularization. 4 It has been demonstrated that the degree of myocardial salvage assessed by SPECT is an independent predictor of outcome in patients with acute myocardial infarction. 5 Moreover, SPECT perfusion imaging provides other useful information with diagnostic and prognostic value such as regional wall motion and thickening, ejection fraction and left ventricular geometry indices. [6] [7] [8] Another tracer that can be used in the evaluation of AAR and of the extent of myocardial salvage is the 123 Ib-methyliodo-phenyl pentadecanoic acid ( 123 I-BMIPP). Rest imaging of 123 I-BMIPP is related to its metabolism in the mitochondria. After an ischemic event, during the subacute phase ([ 6 hours) there is a reduction of 123 I-BMIPP uptake in the affected territory, even after successful reperfusion therapy, with recover in the chronic phase (30 days). 9 It has been demonstrated that the size of AAR assessed by 123 I-BMIPP imaging at 7 days after myocardial infarction is similar to perfusion defect evaluated by SPECT perfusion imaging performed at cath lab time, with the advantage to being able to schedule the examination when the patient is more stable. 10 In the present issue of the Journal, Yoshida et al. 11 compared the effect of prasugrel and clopidogrel on myocardial salvage, assessed by 123 I-BMIPP imaging at 7 days after the reperfusion therapy and 99m-Tc-tetrofosmin SPECT 3 months after revascularization.
According to current guidelines, 12, 13 to reduce the risk of post-procedural thrombotic events, dual antiplatelet therapy (DAPT) consisting of aspirin in addition to a potent P2Y12 inhibitor (prasugrel or ticagrelor), or clopidogrel if these are not available or are contraindicated, is generally recommended for 12 months following percutaneous coronary intervention (PCI) for STEMI,. Prasugrel is currently the most-used drug due to its proven stability over time, which has been attributed to a fast and complete generation of its active metabolite. 14 Conversely, clopidogrel is not in the firstline therapy due to its variable effect on ADP-induced platelet aggregation, with an efficacy ranging from 0% to 100%. 15 Polymorphisms of genes encoding cytochromes that are involved in generation of clopidogrel active metabolites influence the antiplatelet action of the drug. 16 Several methods have been proposed to identify significant genetic variants, in particular in the CYP2C19 gene.
A recent paper reviewed the state-of-art of both platelet function and genetic testing for guiding P2Y 12 receptor inhibitor therapy in PCI. 17 These latter approaches may be useful when DAPT escalation or deescalation is an option; however, only one study demonstrated a benefit of tailoring the antiplatelet regimen according to platelet function testing. 18 It should be considered that not only genetic variants affect clopidogrel activity but also other factors, such as gastrointestinal absorption, drug interactions, and therapy adherence are involved. Therefore, genotyping data cannot be considered a surrogate for platelet function test to assess antiplatelet response.
Yoshida et al. 11 investigation has the merit to bring to the fore the discussion on the usefulness of platelet function tests, particularly in patients in whom DAPT is mandatory. It has been demonstrated that a high ontreatment platelet reactivity is associated with ischemic events while a low on-treatment platelet reactivity is associated with bleeding. 19 In the current study, 11 platelet function test was performed using a whole blood aggregometer based on the screen filtration pressure method. However, the prevalence of high and low-platelet reactivity may differ significantly between assays, and several laboratorybased methods, (Light Transmission Aggregometry, Multiple Electrode Aggregometry, Platelet Function Analyser (PFA)-100, Vasodilator-Stimulated Phosphoprotein (VASP) assay), and point-of-care or nearpatient-based assay (VerifyNow, Multiplate, Thromboelastography) have been proposed. 20 Till now, no single test has been proven superior, although Veri-fyNow, PFA-100 and VASP are the most commonly used. Future trials are needed to determine the best method to analyze platelet function for clinical purpose, in particular in the setting of PCI.
Then again, the main finding of this study 10 is that prasugrel in STEMI patients was associated with a higher degree of myocardial salvage compared with clopidogrel in the presence of high-platelet reactivity. This is the first investigation of direct comparison between two P2Y12 inhibitors using SPECT imaging. However, other imaging techniques have been used to compare P2Y12 inhibitors efficacy.
In the REDUCE-MVI 21 study, CMR was performed during the acute phase and at 1 month in 110 patients with STEMI treated with a loading dose (180 mg) of ticagrelor and randomized to maintenance therapy of ticagrelor or prasugrel after primary PCI. The Authors found that ticagrelor maintenance therapy was not superior to prasugrel in preventing coronary microvascular injury in the infarct-related territory as assessed by the index of microcirculatory resistance, and this resulted in a comparable infarct size at 1 month. In a subgroup of 94 patients (85%), no differences in platelet inhibition and high and low-platelet reactivity were observed between the 2 treatment groups after 1 month of maintenance therapy.
Non-invasive imaging methods are widely used to estimate and to monitor therapy effects and efficacy. Thus, there is great interest in consistent techniques development that may provide standardized measurements of therapy effect translating imaging findings themselves into surrogate end-points for outcome prediction. All this effort takes as finish line a personalized approach to timely optimal therapy for ever more patient-tailored precision medicine.
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